Replies to post #101832 on Biotech Values

[jq1234]

Current Abraxane sales are around $300m, but growing at 25% a year. If the drug succeeds in other indications like lung and pancreatic (it has a good shot in both in my view), then peak sales in excess of $2 billion are plausible.

CELG just paid around $2.8 billion plus some milestones for essentially Abraxane alone - the rest of the company isn't much at this point.

No, the revenue for Abraxane in breast cancer has been flat to decline in last 2 years: $315 m in 2009, $335 m in 2008, $325 m in 2007.

CELG stated they expected the acquisition to boost revenue by $1 billion by 2015, which includes from other indictions.